ACORDA THERAPEUTICS INC Form 8-K January 28, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 28, 2008

Acorda Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

000-50513 (Commission File Number)

13-3831168 (I.R.S. Employer Identification No.)

15 Skyline Drive, Hawthorne, NY (Address of principal executive offices)

10532 (Zip Code)

Registrant s telephone number, including area code: (914) 347-4300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 OTHER EVENTS.		
On January 28, 2008, Acorda Therapeutics, Inc. issucopy of the release is attached hereto as Exhibit 99.1		ults from a thorough QT study of Fampridine-SR. A is Item.
ITEM 9.01 FINANCIAL STATEMENTS AND E	EXHIBITS.	
(d) Exhibits		
99.1 Press release dated January 28, 2008.		
	SIGNATURES	
Pursuant to the requirements of the Securities Exchaundersigned hereunto duly authorized.	ange Act of 1934, the registrant has dul	ly caused this report to be signed on its behalf by the
	Acorda Therapeutics,	, Inc.
	Ву:	/s/ David Lawrence
		Name: David Lawrence, M.B.A. Title: Chief Financial Officer
	2	

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated January 28, 2008